| __timestamp | Agios Pharmaceuticals, Inc. | Ascendis Pharma A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 6274000 |
| Thursday, January 1, 2015 | 35992000 | 9415000 |
| Friday, January 1, 2016 | 50714000 | 11504000 |
| Sunday, January 1, 2017 | 71124000 | 13482000 |
| Monday, January 1, 2018 | 114145000 | 25057000 |
| Tuesday, January 1, 2019 | 132034000 | 48473000 |
| Wednesday, January 1, 2020 | 149070000 | 76669000 |
| Friday, January 1, 2021 | 121445000 | 160180000 |
| Saturday, January 1, 2022 | 121673000 | 221227000 |
| Sunday, January 1, 2023 | 119903000 | 264410000 |
| Monday, January 1, 2024 | 156784000 | 284545000 |
Data in motion
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Ascendis Pharma A/S and Agios Pharmaceuticals, Inc. have been on this journey since 2014, each with unique strategies. Over the past decade, Ascendis Pharma has seen a staggering increase in SG&A expenses, rising from approximately $6 million in 2014 to over $264 million in 2023. This represents a growth of over 4,100%, reflecting their aggressive expansion and investment in administrative capabilities.
Conversely, Agios Pharmaceuticals has maintained a more moderate trajectory, with SG&A expenses growing from around $19 million in 2014 to nearly $120 million in 2023, marking a 530% increase. This suggests a more controlled approach to cost management. As these companies continue to evolve, their ability to optimize SG&A costs will be pivotal in determining their long-term success in the biotech arena.
Breaking Down SG&A Expenses: Eli Lilly and Company vs Agios Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Ascendis Pharma A/S
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Ascendis Pharma A/S
Who Optimizes SG&A Costs Better? Ascendis Pharma A/S or Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Ascendis Pharma A/S vs Dynavax Technologies Corporation
Comparing SG&A Expenses: Ascendis Pharma A/S vs Xencor, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Pharming Group N.V. or Agios Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Xenon Pharmaceuticals Inc. and Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Wave Life Sciences Ltd.
Selling, General, and Administrative Costs: Agios Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.